BioSpace News Archive

Microbot Medical Inc. announced the appointment of Aileen Stockburger to the Company’s Board of Directors, effective April 1, 2020.

Pandion Therapeutics, Inc., a clinical-stage, privately-held biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that it has closed an $80 million Series B financing

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2019 and announced recent business highlights.

New Service overcomes challenges of manufacturing difficult neoantigen peptides critical to personalized cancer vaccine and T-cell therapy generation

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced that it has begun a cooperative research effort with University of Virginia Health (UVA) and the Integrated Translational Research Institute of Virginia (

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today provided an update on its business strategy and financial position in light of the current COVID-19 situation.

Santen Inc., a U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, today announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical

Richard Hague appointed President and will continue as Chief Operating Officer SALT LAKE CITY--( BUSINESS WIRE )-- PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that the Company’s Board of Directors has restructured the executive team to more appropriately align with traditional management structures, dissolving the Office of the Chief Executive, w

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), today signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc., a preclinical-stage biotechnology company based in Cambridge, MA.

Today, the ASH Research Collaborative’s (ASH RC) Data Hub launched the ASH RC Data Hub COVID-19 Registry for Hematologic Malignancy, a global registry with clinical data exclusively on people with COVID-19 and a current or past diagnosis of a hematologic malignancy.